Black Rock Inc. Praxis Precision Medicines, Inc. Transaction History

Black Rock Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$0.87 - $1.71 $1.11 Million - $2.17 Million	1,270,920 Added 210.44%	1,874,843 $3.21 Million
Q2 2023 Aug 11, 2023	SELL	$0.83 - $1.18 $1.9 Million - $2.7 Million	-2,284,358 Reduced 79.09%	603,923 $694,000
Q1 2023 May 12, 2023	SELL	$0.8 - $4.98 $66,784 - $415,735	-83,481 Reduced 2.81%	2,888,281 $2.34 Million
Q4 2022 Feb 13, 2023	SELL	$1.88 - $36.45 $512,187 - $9.93 Million	-272,440 Reduced 8.4%	2,971,762 $7.07 Million
Q3 2022 Nov 14, 2022	BUY	$2.5 - $37.95 $683,600 - $10.4 Million	273,440 Added 9.2%	3,244,202 $7.37 Million
Q2 2022 Aug 12, 2022	BUY	$1.75 - $11.34 $771,751 - $5 Million	441,001 Added 17.43%	2,970,762 $7.28 Million
Q1 2022 May 12, 2022	BUY	$10.21 - $20.29 $337,593 - $670,888	33,065 Added 1.32%	2,529,761 $25.8 Million
Q4 2021 Feb 10, 2022	BUY	$16.76 - $22.99 $5.9 Million - $8.09 Million	352,027 Added 16.41%	2,496,696 $49.2 Million
Q3 2021 Nov 09, 2021	BUY	$13.15 - $22.56 $8.29 Million - $14.2 Million	630,696 Added 41.66%	2,144,669 $39.7 Million
Q2 2021 Aug 11, 2021	BUY	$18.28 - $33.05 $27.7 Million - $50 Million	1,513,973 New	1,513,973 $27.7 Million

75K

Ticker PRAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,576,100
Market Cap $3.4B
Description
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of ...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.